BioPharma Credit (BPCR) has announced it has entered (alongside the BioPharma V fund) two five-year senior secured loan agreements with a total commitment of US$85m over the next 12 months (of which US$52.5m will be drawn initially). The terms of both loans are broadly in line with previous deals with a high single-digit floating interest rate, a 2% upfront fee and certain make-whole/prepayment fees. We estimate that BPCR still has at least US$344m in uncommitted cash (after excluding the rec
14 Nov 2019
BioPharma Credit - Invests in Epizyme and Akebia
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BioPharma Credit - Invests in Epizyme and Akebia
BioPharma Credit PLC USD (BPCR:LON) | 87.7 0 0.0% | Mkt Cap: 1,084m
- Published:
14 Nov 2019 -
Author:
Milosz Papst -
Pages:
3
BioPharma Credit (BPCR) has announced it has entered (alongside the BioPharma V fund) two five-year senior secured loan agreements with a total commitment of US$85m over the next 12 months (of which US$52.5m will be drawn initially). The terms of both loans are broadly in line with previous deals with a high single-digit floating interest rate, a 2% upfront fee and certain make-whole/prepayment fees. We estimate that BPCR still has at least US$344m in uncommitted cash (after excluding the rec